pfirmann: eutos preferable to sokal in cml
Published 8 years ago • 158 plays • Length 3:42Download video MP4
Download video MP3
Similar videos
-
1:19
"abeloff's clinical oncology", 5th edition
-
0:54
qol survey for acute leukemias
-
1:35
aml in 2022 and beyond
-
1:19
real-world outcomes of liso-cel therapy in r/r dlbcl
-
2:46
dr victor llombart - leukaemia uk john goldman fellow 2022
-
1:56
the efficacy of olutasidenib in patients with r/r idh-mutant aml
-
2:12
new targeted therapies in chronic lymphocytic leukaemia (cll)
-
1:40
vulnerabilities in lipid synthesis pathways and resistance to imids and celmods in multiple myeloma
-
2:01
toyota etios safety tests latin ncap | july 2019 ratings
-
1:05:32
narrative economics with nobel prize-winner robert shiller | lse online event
-
2:33
the effect of lymphodepleting agents on rate and severity of toxicities following car-t infusion
-
55:07
oncology& hematology shadowing session with dr. zhuoyan li
-
2:10
novel clinical tool for clonal hematopoiesis identifies high risk for blood cancer patients
-
1:10
targeting chemokines in lymphoma
-
3:48
predictor factors of lymphadema: recent discoveries
-
1:01
cll resistance mechanisms in the era of novel agents
-
1:04
horizon scan of novel and upcoming aml therapies
-
0:52
medical breakthrough
-
4:28
comparison of cartitude-1 outcomes vs real world clinical practice observed in german registry
-
1:12
exciting advances in dlbcl: molecular characterization of subtypes & novel immunotherapeutic agents
-
1:00
beat aml: dr. louis degennaro, president & ceo
-
2:36
novel non-immunological agents currently under investigation for cll